Posting of AR and Accounts and Notice of AGM

RNS Number : 7906I

ReNeuron Group plc

16 August 2021

 

ReNeuron Group plc

("ReNeuron" or the "Company")

  Posting of Annual Report and Accounts and Notice of AGM

ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31  March 2021 and the Notice of the 2021 Annual General Meeting ("AGM") have today been sent to shareholders and are also available on the Company's website at  www.reneuron.com .

ReNeuron's AGM will be held at 10.00am on Thursday 16 September 2021 in the Hilton London Paddington, 146 Praed Street, London, W2 1EE.

At the time of publication of the notice of AGM, the Government has lifted most legal restrictions relating to public gatherings that had previously been in place due to the ongoing COVID-19 Pandemic. In line with this, the Board welcomes the opportunity to invite shareholders to attend the AGM in person. Should this situation change, shareholders will be notified though our website www.reneuron.com and, where appropriate by RNS.

Shareholders are encouraged to send any questions for the Chairman to   [e-mail] at least 48 hours prior to the meeting. Where appropriate, such questions and answers will be collated and later published, together with full voting details, in the Investor Centre of the Company's website at  www.reneuron.com .

ENDS

Contacts:

ReNeuron	www.reneuron.com/investors
Olav Hellebø, Chief Executive Officer	Via Walbrook PR
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace	[phone]
Allenby Capital Limited (Joint Broker)	[phone]
James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)	[phone] or [e-mail]
Paul McManus, Alice Woodings	[phone] / [phone]

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

 

END

 

 

NOADKABDNBKDNFD